Search
Connecticut Paid Clinical Trials
A listing of 1248 clinical trials in Connecticut actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
793 - 804 of 1248
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Recruiting
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Multiple Myeloma
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Recruiting
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Smilow Cancer Center at YNHH, New Haven, Connecticut
Conditions: Myelofibrosis
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Previously Treated Non-Small Cell Lung Cancer
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients with Advanced Solid Tumors
Recruiting
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined.
Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211.
Part 3 is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven, North Haven, Connecticut
Conditions: Advanced Solid Tumors
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
Recruiting
Chronic neuropathic pain (CNP) is disabling. Research on frontline treatments for CNP, shows inconsistent outcomes and dissatisfaction among Veterans. Veterans and clinicians have shown significant interest in cannabis derivatives (THC, CBD) for neuropathic pain control, but there are no well-controlled trials guiding expectations for benefit and adverse outcomes associated with cannabis for CNP. Because Veterans are likely to present with pain and pain-related polymorbidity significantly differ... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/11/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Diabetic Neuropathic Pain, Peripheral Neuropathic Pain
Gastroschisis Outcomes of Delivery (GOOD) Study
Recruiting
The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a randomized, prospective, multi-institutional trial across NAFTNet-affiliated institutions. Patients may be enrolled in the study any time prior to 33 weeks, but will be randomized at 33 weeks to delivery at 35 weeks o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Gastroschisis
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Recruiting
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: West Haven VA Medical Center, West Haven, Connecticut
Conditions: Cirrhosis, Ascites Hepatic
SNV1521 in Participants with Advanced Solid Tumors
Recruiting
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Advanced Solid Tumor
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
SV2 PET Imaging with [11C]APP311
Recruiting
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/10/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Recruiting
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous thromboembolism.
The main objective is to provide information on the Internet to help physicians to improve their knowledge on the natural history of thromboembolic disease, particularly in those subgroups of patients who are usually not recruited in randomized clinical trials (... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/10/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Venous Thromboembolism